Last reviewed · How we verify

SD-QIV

McGill University Health Centre/Research Institute of the McGill University Health Centre · FDA-approved active Biologic

SD-QIV is a quadrivalent influenza vaccine that stimulates immune responses against four strains of influenza virus.

SD-QIV is a quadrivalent influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.

At a glance

Generic nameSD-QIV
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Drug classInactivated influenza vaccine
ModalityBiologic
Therapeutic areaImmunology/Infectious Disease
PhaseFDA-approved

Mechanism of action

SD-QIV contains inactivated influenza virus antigens representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. It is administered as an intramuscular injection to induce both humoral and cellular immune responses that protect against infection with these circulating influenza strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: